Clinical trials: Myeloma-Multiple
Anemia, Multiple Myeloma
The Effect of Epoetin Alfa on the Anemia of Patients With Multiple Myeloma
The purpose of this study is to evaluate the safety and effectiveness of epoetin alfa versus placebo in reducing the transfusion requirements in anemic patients with multiple myeloma, and to investigate the quality-of-life…
- Trial name
- NCT00270101
- Testing
- epoetin alfa
- Volunteers
- 156 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Acute Myeloid Leukemia, AML, Adult
FT538 in Subjects With Advanced Hematologic Malignancies
This is a Phase I dose-finding study of FT538 as monotherapy in acute myeloid leukemia (AML) and in combination with monoclonal antibodies in multiple myeloma (MM).
- Conditions
- Acute Myeloid Leukemia, AML, Adult, Multiple Myeloma, Myeloma
- Trial name
- NCT04614636
- Testing
- FT538, Cyclophosphamide, Fludarabine
- Where
- 8 sites in United States
- Volunteers
- 42 people
- Sponsor
- Fate Therapeutics
Multiple Myeloma
A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib
H9S-MC-JDCF was a multicenter non-randomized, single-arm, open-label, dose-escalation, dose confirmation, Phase 1 study of intravenous (IV) LY2127399 in combination with bortezomib in patients with refractory or relapsed MM.
- Trial name
- NCT00689507
- Testing
- LY2127399
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- Applied Molecular Evolution
Multiple Myeloma
Integrating Touchscreen-based Geriatric Assessment and Frailty Screening for Adults With Multiple Myeloma
The overarching objective of this study is to evaluate the feasibility, usability, and acceptability of an abbreviated, tablet-based geriatric assessment in a population of older adults with multiple myeloma.
- Trial name
- NCT03068637
- Testing
- Carevive CPS
- Where
- 2 sites in United States
- Volunteers
- 165 people
- Sponsor
- Carevive Systems, Inc.
Multiple Myeloma
Quality of Life of Non-transplant Candidate Multiple Myeloma Patients Treated With Early Bortezomib
This study will observe the degree of the quality of life in non-transplant candidate patients with multiple myeloma before and after bortezomib administration by using EORTC-QLQ C30 (European Organization for Research and…
- Trial name
- NCT01060202
- Testing
- No intervention
- Volunteers
- 60 people
- Sponsor
- Janssen Korea, Ltd., Korea
Multiple Myeloma, Myeloma
Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
The purpose of this study is to determine how well newly diagnosed multiple myeloma patients respond to an experimental regimen of Vincristine, DOXIL (doxorubicin HCl liposome injection) and Dexamethasone (VDD) versus the…
- Conditions
- Multiple Myeloma, Myeloma, M-Protein, Myeloma Proteins
- Trial name
- NCT00344422
- Testing
- Vincristine, DOXIL (doxorubicin HCl liposomal injection), and Dexamethasone (VDD) vs. Vincristine, Doxorubicin and Dexamethasone (VAD)
- Volunteers
- 198 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Relapsed/Refractory Multiple Myeloma (RRMM)
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
The purpose of this study is to describe the use of teclistamab/talquetamab in the treatment of patients with RRMM outside of clinical trials.
- Trial name
- REALiTEC/TAL (NCT06285318)
- Testing
- Teclistamab, Talquetamab
- Where
- 68 sites in Denmark, France and 9 more
- Volunteers
- 900 people
- Sponsor
- Janssen-Cilag Ltd.
Multiple Myeloma
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
This is a phase 1/2 multicenter, open-label, first-in-human study of IBI3003. It includes a phase 1 dose escalation and expansion section to identify maximum tolerated dose(MTD)/recommended Phase 2 Dose(RP2D) of IBI3003, plans to…
- Trial name
- NCT06083207
- Testing
- IBI3003
- Where
- 13 sites in Australia, China
- Volunteers
- 116 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Multiple Myeloma
PRospective Multiple Myeloma Impact Study
This will be a prospective, case-only, study to measure the impact of MMprofiler on treatment intention decisions in Multiple Myeloma patients.
- Trial name
- PROMMIS (NCT02911571)
- Testing
- MMprofiler SKY92 gene signature
- Where
- 9 sites in United States
- Volunteers
- 250 people
- Sponsor
- SkylineDx
Relapsed or Refractory Multiple Myeloma (RRMM)
A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma
A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing F182112 with Standard of Care in Patients with Relapsed or Refractory Multiple Myeloma
- Trial name
- NCT07579234
- Testing
- F182112 single-agent, Pomalidomide + Bortezomib + Dexamethasone (PVd) or Selinexor + Bortezomib + Dexamethasone (SVd)
- Where
- China
- Volunteers
- 261 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Multiple Myeloma (MM), Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
The main aims of this 2-part study are: Phase I: To determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of IDP-121 in patients with multiple myeloma (MM), diffuse large B cell lymphoma not otherwise…
- Conditions
- Multiple Myeloma (MM), Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double Hit Lymphoma, High Grade B-Cell Lymphoma, Not Otherwise Specified
- Trial name
- CASSANDRA (NCT05908409)
- Testing
- IDP-121
- Where
- 11 sites in Spain
- Volunteers
- 37 people
- Sponsor
- IDP Discovery Pharma S.L.
Multiple Myeloma, Plasma Cell Leukemia
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
This is a Phase 1 study during which patients with relapsed or refractory multiple myeloma (MM) or plasma cell leukemia (PCL) will receive investigational study drug ARRY-520 and bortezomib, with or without dexamethasone, with…
- Trial name
- NCT01248923
- Testing
- ARRY-520, KSP(Eg5) inhibitor; intravenous, Bortezomib, proteasome inhibitor; intravenous or subcutaneous, Dexamethasone, steroid; oral
- Where
- 13 sites in United States
- Volunteers
- 55 people
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
Multiple Myeloma
Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
This is a two-stage phase 1b/2a, open-label, multicenter, dose-escalation study of STI-6129 administered intravenously once in a 4-week cycle in subjects with relapsed or refractory multiple myeloma.
- Trial name
- NCT05308225
- Testing
- STI-6129
- Where
- 3 sites in United States
- Volunteers
- 72 people
- Sponsor
- Sorrento Therapeutics, Inc.
Multiple Myeloma
A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)
This is a first-in-human, open-label, uncontrolled, multi-center, monotherapy, dose-escalation and dose expansion study. Forimtamig will be administered to participants with r/r MM for whom no standard-of-care treatment exists or…
- Trial name
- NCT04557150
- Testing
- Forimtamig
- Where
- 20 sites in Australia, Belgium and 7 more
- Volunteers
- 225 people
- Sponsor
- Hoffmann-La Roche
Multiple Myeloma
Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma
The primary objective of the study is to determine the safety and tolerability of I-131-CLR1404 as a single or multiple dose, with and without concurrent weekly dexamethasone, in patients with relapsed or refractory multiple…
- Trial name
- NCT02278315
- Testing
- I-131-CLR1404, dexamethasone
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- Cellectar Biosciences, Inc.
Multiple Myeloma
Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma
The purpose of this research study is to test the safety and effectiveness of replacing vincristine with a drug called bortezomib (also known as "Velcade"or PS341) in the standard therapy vincristine, doxorubicin (not limited to…
- Trial name
- NCT00441168
- Testing
- adriamycin, bortezomib, dexamethasone
- Where
- 16 sites in Croatia, Germany and 5 more
- Volunteers
- 30 people
- Sponsor
- Janssen-Cilag International NV
Multiple Myeloma
Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma
The purpose of this study is to determine the highest tolerated dose, safety and activity of HCD122 in patients with Multiple Myeloma who are relapsed after receiving prior treatment.
- Trial name
- NCT00231166
- Testing
- HCD122
- Where
- 7 sites in United States, Australia
- Volunteers
- 33 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
The purpose of Phase 1 of this study was to determine the safety, tolerability, maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of oral ixazomib administered in combination with lenalidomide and low-dose…
- Trial name
- NCT01217957
- Testing
- Ixazomib, Lenalidomide, Dexamethasone
- Where
- 16 sites in United States
- Volunteers
- 65 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma
Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma
This study is an open-label, multicenter Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of HRS-3738 in patients with recurrent and refractory Non-Hodgkin's lymphoma and multiple myeloma.
- Trial name
- NCT05363800
- Testing
- HRS-3738
- Where
- 3 sites in China
- Volunteers
- 74 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Multiple Myeloma
PHA-739358 for the Treatment of Multiple Myeloma
The purpose of this study is to determine the antitumor activity of PHA-739358 as single agent IV infusion in adult patients with Multiple Myeloma who have a history of at least 2 previous lines of treatment for the disease.
- Trial name
- NCT00872300
- Testing
- PHA-739358
- Where
- 4 sites in United States, France
- Volunteers
- 7 people
- Sponsor
- Nerviano Medical Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.